Intrathecal Methotrexate Treatment in Multiple Sclerosis

Publication Date

November 1, 2010

Publication Information

Sadiq SA, Simon EV, and Puccio LM. Journal of Neurology. 2010; 257(11): 1806-1811.

This study reports on the feasibility of using intrathecal methotrexate (ITMTX) in treatment unresponsive multiple sclerosis (MS) patients with progressive forms of the disease. A retrospective, open-label, chart review analysis was conducted following patients (n = 121) with MS for up to eight treatments given every 8-11 weeks. Patients were considered for ITMTX treatment if they were unresponsive to or intolerant of FDA-approved treatments. There was a 1 year follow-up after their eighth or last treatment (if discontinued earlier). Patients underwent neurological assessments and expanded disability status scale (EDSS) evaluations. No serious adverse effects were noted during the study period. In 87 secondary progressive MS patients, EDSS scores were stable or improved in 89%, with significantly improved mean EDSS post-treatment compared to baseline (P = 0.014). Of 34 primary progressive patients, EDSS scores were stable in 82%, with no significant progression in EDSS post-treatment compared to baseline. ITMTX may have a beneficial role in progressive forms of MS and is well tolerated with no serious adverse events.

Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Privacy Policy

 

Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.